Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%# EBITDA at Rs 787 …
Jan 30, 2025 · Financial Commentary: Q3FY25. Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore.Reported 7% YoY growth on a like-for-like basis, after adjusting for Branded …
OFF
Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs 787 …
2 weeks from now
Jan 30, 2025 · Financial Commentary: Q3FY25. Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore.Reported 7% YoY growth on a like-for-like basis, after adjusting for Branded …
biocon.com
OFF
Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs …
2 weeks from now
Jan 30, 2025 · Biocon Q3FY25 Revenue at Rs 3,856 #Cr, Up 7% EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr Biosimilars^ Up 14%; Research Services Up 11% Bengaluru, …
biocon.com
OFF
F A C T S H E E T - Biocon.com
2 weeks from now
TOTAL REVENUE 3,856 4,519 -15% EXPENDITURE Material & Power costs 1,454 1,320 10% ... Other expenses 686 823 -17% Manufacturing, staff & other expenses 3,070 3,027 1% EBITDA …
biocon.com
OFF
Biocon In Q3FY25 Generated Revenue Of Rs. 3,856 Crore, Net Profit …
2 weeks from now
Jan 31, 2025 · Core EBITDA at Rs. 1,007 crore is up 4% on a like-for-like basis, with core operating margins of 26%. Net R&D investments for the quarter were Rs. 199 crore, …
pharmabiz.com
OFF
Press Releases - Biocon Biologics - Global Biopharmaceutical …
2 weeks from now
Jan 30, 2025 · Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7% # EBITDA at Rs 787 Cr, Up 16% #; Net Profit at Rs 25 Cr. Jan 30, 2025 Biocon’s S&P Global ESG Score Improves to 69 for …
bioconbiologics.com
OFF
General Announcement::Press Release
2 weeks from now
Jan 30, 2025 · BIOCON BIOLOGICS GLOBAL PLC Securities BIOCONBIO US$800M6.67%N291009A - US090978AA56 - RJUB ... Biocon Q3FY25 Revenue at Rs 3,856 …
sgx.com
OFF
Biocon Q3 Results: Profit Plummets 96%; Misses Estimates
2 weeks from now
Jan 30, 2025 · Biocon Ltd.'s Q3FY25 consolidated net profit plummeted 96% to Rs 25 crore, falling short of analysts' estimates. ... in the third quarter as well as gain from Biocon’s stake …
ndtvprofit.com
OFF
Biocon Q3 Results: All Business Segments Grow; EBITDA Up 16%, …
2 weeks from now
Jan 30, 2025 · Total revenue for the quarter was ₹3,856 crore, marking a 7% increase. EBITDA came in at ₹787 crore, up 16% from the previous year. Also read: GAIL Q3 Results: Stock …
cnbctv18.com
OFF
Biocon Buys Back An Investor Stake In Biologics Unit, Posts Rs 25 …
2 weeks from now
Jan 30, 2025 · Biocon on Thursday said its board has approved to acquire 1.5% equity share capital for Rs 550 crore in Biocon Biocon buys back an investor stake in biologics unit, posts …
theadvisertimes.com
OFF
Biocon Buys Back An Investor Stake In Biologics Unit, Posts Rs 25 …
2 weeks from now
Jan 30, 2025 · Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, …
indiatimes.com
OFF
Biocon Q3FY24 Revenue At Rs 4,519 Cr, Up 50%; Biosimilars Up …
2 weeks from now
Feb 8, 2024 · Net R&D investments for the quarter were Rs 329 crore, representing 11% of revenue ex-Syngene. Core EBITDA at Rs 983 crore, represents core operating margins of …
biocon.com
OFF
Biocon Q3FY23 Revenue At Rs 3,020 Cr, Up 36%; Biosimilars Up …
2 weeks from now
Mar 9, 2023 · EBITDA at Rs 723 Cr, Up 35%; Core EBITDA at Rs 1,069 Cr, Up 49%; Net Profit (excluding exceptional items) at Rs 140 Cr Bengaluru, Karnataka, India: February 14, 2023: …
bioconbiologics.com
OFF
Biocon Q3FY22 Revenue At Rs 2,223 Cr, Up 18%; EBITDA At Rs 537 …
2 weeks from now
Jan 20, 2022 · Q3FY22 Revenue at Rs 607 Crore, up 7% YoY, 15% QoQ Commenting on the Generics segment performance, Siddharth Mittal, CEO & Managing Director, Biocon Limited , …
bioconbiologics.com
OFF
Biocon Q1FY25 Revenue Up 30% At Rs 4,567 Cr EBITDA Up 117
2 weeks from now
Aug 8, 2024 · Financial Commentary: Q1FY25 . Total Consolidated Revenue for Q1FY25 grew 30% year-on-year (YoY) to Rs 4,567 crore.. Other Income includes proceeds of Rs 1,057 …
biocon.com
OFF
Biocon Q4FY22 Revenue At Rs 2,476 Cr, Up 21%; Core EBITDA At …
2 weeks from now
Apr 28, 2022 · FY22 Revenue at Rs 8,397 Cr, Up 14%; Core EBITDA Up 18% at Rs 2,669 Cr; PBT (before Exceptional Item) at Rs 1094 Cr, Up 4% Bengaluru, Karnataka, India: April 28, …
bioconbiologics.com
OFF
Ankur Chavan - Senior Director IT - Biocon | LinkedIn
2 weeks from now
#Press: #Biocon's #Q3FY25 Operating Revenue up 10% (YoY) on like-for-like basis at Rs 3,821 Cr EBITDA up 16% (YoY) on like-for-like basis at Rs 787… Liked by Ankur Chavan Rajiv …
linkedin.com
OFF
FY23 Revenue At Rs 11,550 Cr, Up 38%; EBITDA At Rs 2,888 Cr …
2 weeks from now
May 23, 2023 · 5 EBITDA for the quarter increases 75% to Rs 1,152 crore, representing an EBITDA margin of 29% versus 27% in the same period last year. Profit Before Tax and …
biocon.com
OFF
Biocon Q4FY21 Revenue At Rs 2,044 Cr, Up 26%; EBITDA At Rs 641 …
2 weeks from now
FY21 Revenue Up 14% at Rs 7,360 Cr; EBITDA Up 8% at Rs 1,907 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 754 Cr. Bengaluru, Karnataka, India: April …
biocon.com
Install CouponFollow Extension on Chrome
Install the CouponFollow extension to search for discount codes when shopping the fastest!
Install CouponFollow Chrome Extension
Listing Store by Characters
